- Home
- / ZAI Lab
ZAI Lab
Revenue
$144.3 M
FY, 2021
Market Capitalization
$4.7 B
2023-01-20
ZAI Lab Summary
Company summary
- Overview
- Zai Lab is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for cancer, autoimmune and infectious diseases. It offers Zejula, a selective small-molecule poly (ADP-ribose) PARP 1/2inhibitor; Optune, a portable device that delivers tumor treating fields; and Qinlock, a switch-control tyrosine kinase inhibitor.
- Type
- Public
- Status
- Active
- Founded
- 2014
- HQ
- CN | view all locations
- Cybersecurity rating
- ESG rating
Key people
Harald Reinhart, Chief Medical Officer, Autoimmune and Infectious Diseases
Billy Cho, Chief Financial Officer
F. Ty Edmondson, Chief Legal Officer
LocationsView all
7 locations detected
Shang Hai Shi HQ
China
Jin Ke Lu, Pu Dong Xin Qu
Cambridge, MA
United States
314 Main St 4th 100
Menlo Park, CA
United States
1440 O'Brien Dr ste a & c
Suzhou, Jiangsu Sheng
China
Building 7&8 Biobay 218 Sangtian Street Suzhou
Bei Jing Shi
China
Xi Da Wang Lu, Chao Yang Qu
Hong Kong, Hong Kong Island
Hong Kong
Room 2301 , 23/F. Island Place Tower 510 King 's Road
ZAI Lab Financials
Summary financials
- Revenue (Q3, 2022)
- $57.5M
- Gross profit (Q3, 2022)
- $39.7M
- Net income (Q3, 2022)
- ($161.2M)
- Cash (Q3, 2022)
- $1.1B
- EBIT (Q3, 2022)
- ($165.1M)
- Enterprise value
- $3.5B
